Cannabinoid Medication for Adults With OCD
Palabras clave
Abstracto
fechas
Verificado por última vez: | 01/31/2020 |
Primero enviado: | 09/11/2016 |
Inscripción estimada enviada: | 09/19/2016 |
Publicado por primera vez: | 09/21/2016 |
Última actualización enviada: | 02/26/2020 |
Última actualización publicada: | 02/27/2020 |
Fecha de los primeros resultados enviados: | 01/09/2020 |
Fecha de los primeros resultados de CC enviados: | 02/26/2020 |
Fecha de los primeros resultados publicados: | 02/27/2020 |
Fecha de inicio real del estudio: | 08/31/2016 |
Fecha estimada de finalización primaria: | 12/31/2018 |
Fecha estimada de finalización del estudio: | 12/31/2018 |
Condición o enfermedad
Intervención / tratamiento
Drug: Nabilone
Behavioral: Nabilone and EX/RP
Fase
Grupos de brazos
Brazo | Intervención / tratamiento |
---|---|
Experimental: Nabilone Will receive nabilone at 1 mg daily (BID) over 4 weeks. | |
Experimental: Nabilone and EX/RP Will receive nabilone at 1 mg daily (BID) plus therapist-guided Exposure and Response Prevention Therapy during 4 weeks. | Behavioral: Nabilone and EX/RP Exposure and Response Prevention Therapy (EX/RP) is a type of Cognitive-Behavioral Therapy for OCD that involves intentionally confronting situations that trigger obsessional distress while refraining from doing compulsions. |
Criterio de elegibilidad
Edades elegibles para estudiar | 18 Years A 18 Years |
Sexos elegibles para estudiar | All |
Acepta voluntarios saludables | si |
Criterios | Inclusion Criteria: - Age 18-60 - Physically healthy, not pregnant - Primary Obsessive-Compulsive Disorder (OCD) - Patient off all psychotropic (except selective serotonin reuptake inhibitors [SSRIs]) and other types of drugs likely to interact with nabilone - Ability to provide informed consent - Ability to tolerate a treatment free-period Exclusion Criteria: - History of any significant medical condition that may increase the risk of participation - Females who are pregnant or nursing - Current or lifetime history of psychiatric disorders other than OCD that may increase the risk of participation (e.g. lifetime psychosis or bipolar disorder) - Current substance use disorder or positive urine toxicology at screening, or any adverse reaction to a cannabinoid - Patients already receiving EX/RP |
Salir
Medidas de resultado primarias
1. Change in Yale-Brown Obsessive Compulsive Scale [Baseline (Week 0) and Week 4]
Medidas de resultado secundarias
1. Feasibility of Recruitment [Through study completion, an average of 1 year.]